This human tissue allograft is supplied by BONE BANK ALLOGRAFTS (BBA) and was processed and prepared by Texas Human Biologics (THB). All recovery, processing and distribution costs were reimbursed in part by BONE BANK ALLOGRAFTS in accordance with NOTA.

Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta, the area in which the human fetus grows and develops within the mother’s uterus. Human amniotic membrane consists of collagen layers including: (1) basement membrane (2) stromal matrix.

This allograft is supplied sterile.

REGULATORY CLASSIFICATION

This allograft is a human tissue product for transplantation. It is processed and distributed in accordance with FDA requirements for Human Cellular and Tissue-based Products (HCT/P) (21 CFR Part 1271), State regulations, and the Standards of the American Association of Tissue Banks (AATB).

Caution: Federal Law restricts this product to sale by or on the order of a licensed practitioner.

APPLICATIONS FOR USE

This allograft may be used as a wound covering in various surgical procedures. It may be used independently or in combination with autologous tissue or other forms of allograft tissue.

This allograft is intended for single patient use only.

DONOR RECOVERY AND SCREENING

After authorization for donation is obtained (represented by the mothers of the newborn children), collection of the donor tissue is performed in an aseptic manner by appropriately licensed tissue establishments. Donor eligibility is carefully evaluated as required by the US FDA and in accordance with AATB Standards and applicable State guidelines. Tissue donors are evaluated for high risk behaviors and relevant communicable diseases. Screening includes a review of the donor medical and social history, a physical assessment, serological screening, and tissue collection microbiology.

Each donor is tested and shown to be negative or nonreactive for the following:
- Human Immunodeficiency Virus Type 1 Antibody
- Human Immunodeficiency Virus Type 2 Antibody
- Hepatitis C Virus Antibody
- Hepatitis B Surface Antigen
- Hepatitis B Core Antibody (total)
- Syphilis Rapid Plasma Reagin or Treponemal Specific Assay
- HIV/HCV Nucleic Acid Test (NAT)
- Human T-Cell Lymphotropic Virus Type I Antibody (not required)
- Human T-Cell Lymphotropic Virus Type II Antibody (not required)

This testing is performed by a laboratory registered with FDA to perform donor testing and certified to perform such testing on human specimens under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493, or that has met equivalent requirements as determined by the Centers for Medicare and Medicaid Services (CMS). Test kits used are approved by the FDA.

BONE BANK ALLOGRAFTS’ Medical Director has determined this donor tissue to be suitable for transplantation. The testing and medical release records are maintained by BONE BANK ALLOGRAFTS.

PROCESSING

Allograft tissues are processed in a controlled environment using methods designed to prevent contamination and cross contamination. Proprietary physiological buffers and surfactants are used during processing. Allograft tissue may contain traces of these processing agents. Final products are sized and packaged according to approved specifications and procedures and are sterilized using gamma irradiation in accordance with ISO 11137 standards.

Note: Allograft tissues will naturally vary in color from white, off-white, pink, pale pink, and yellow to pale yellow. Occasional dark spots or localized discoloration is a normal occurrence.

CONTRAINDICATIONS

Contraindications for the use of this allograft shall be determined by a licensed practitioner.

WARNINGS

Careful donor screening, laboratory testing, tissue processing, and gamma irradiation have been utilized to minimize the risk of transmission of relevant communicable diseases to the patient. As with any processed human donor tissue, this graft cannot be guaranteed to be free of all pathogens.

Do NOT reuse or re-sterilize.

PACKAGING AND LABELING

Each allograft distributed by BONE BANK ALLOGRAFTS is identified by its own unique serial number. The allograft is packaged in a pouch. Each pouch features a peel back seal and is also heat sealed to provide a sterile barrier. The package label includes graft details such as dimensions. Contents of the package are sterile unless the package is opened or damaged.

Warning: If the innermost pouch is compromised or shows evidence of being torn or opened, DO NOT USE!

Allografts are supplied desiccated and should be stored at room temperature.

STORAGE

Maintain allograft in a clean, dry environment at room temperature (15°C to 30°C). No refrigeration is necessary.

EXPIRATION

See package label for expiration dating.

It is the responsibility of the end-user to maintain this allograft in the appropriate storage conditions prior to transplant and to track expiration date accordingly.

USAGE INSTRUCTIONS

Prior to Usage: Examine Allograft Packaging – Do Not Use This Allograft If:
1. Any part of the package or product elements appear to be missing, tampered with or damaged.
2. The product label or identifying bar code is severely damaged, illegible or missing.
3. The expiration date shown on the package label has passed.

If any of the above conditions exist or are suspected, this allograft should NOT be used.
Preparation of Allograft For Use:
Once a package seal has been compromised, the tissue shall be either transplanted, if appropriate, or properly discarded. Used allograft containers should be disposed of in accordance with recognized procedures for discarding medical waste material.

1. Prepare the allograft for use in accordance with the following procedures:
   a) Open the outer kapak to expose and remove the 1st inner peel pouch.
   b) Open the 1st inner peel pouch and deliver the innermost sterile sealed pouch containing the graft material to a sterile field.
   c) Open the sterile sealed pouch and carefully deliver the graft to a sterile field for transplantation. PLEASE USE CAUTION WHEN REMOVING ALLOGRAFT FROM POUCH AS THE ALLOGRAFT IS THIN AND EXTREMELY LIGHTWEIGHT
   d) Prior to placement on the wound, the allograft may be cut and shaped to the appropriate size required
   e) The graft should then be placed onto the surgical site, using the orientation notch as a guide. Proper orientation (Epithelial side up) is achieved when the graft is held with the notch positioned on the upper right hand side of the allograft. See Orientation Diagram below for further detail.
   f) Absorbable/non-absorbable suture material and/or tissue adhesives may be used to apply the graft to the surgical site, if necessary.
   g) Once applied to the surgical site, the allograft can be hydrated with sterile saline or other sterile solution, if needed.

If for any reason the graft is opened and not used, it should be disposed of properly or returned to BONE BANK ALLOGRAFTS by contacting Client Services and following appropriate return procedures. Document the reason for the non-use of the graft and indicate the disposition of the tissue on the enclosed Transplant Record and return the record to BONE BANK ALLOGRAFTS.

RETURNS
If for any reason tissue must be returned, a return authorization is required from BONE BANK ALLOGRAFTS prior to shipping. It is the responsibility of the health care institution returning the tissue to adequately package and label the tissue for return shipment.

PATIENT RECORD
Recipient records must be maintained for the purpose of tracking tissue post-transplant. IMPORTANT NOTICE TO END-USER: Please record this distinct graft identification code in your records and in the patient’s medical record. It is also recommended that the following information be recorded in the patient’s medical record:

1. Description of Tissue
2. Product Code
3. Expiration Date
4. Description of Procedure
5. Date and Time of Procedure
6. Surgeon Name
7. Any Other Pertinent Information

Please record the patient name, distinct graft identification code, patient date of birth and sex, name and address of the healthcare facility, name of the transplanting physician, date and type of surgery, name of the person filling out the Transplant Record and any comments on the transplant record provided with this unit of allograft tissue. Once completed, the bottom copy of the Transplant Record should be returned to BONE BANK ALLOGRAFTS. Copies of this information should be retained by the transplant facility for future reference.

POTENTIAL COMPLICATIONS
As allografts are composed of proteins such as collagen, the potential for hypersensitivity, allergic reactions or other immune responses may exist. All adverse outcomes potentially attributed to this allograft must be promptly reported to BONE BANK ALLOGRAFTS.

Possible complications can occur with any surgical procedure including, but not limited to pain, infection, hematoma, and/or immune rejection of the introduced tissue.

Disease screening methods are limited; therefore, certain diseases may not be detected.